Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 355-361 , May 2009

In vivo examination of 188Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer

  • Kuo-Ting Chen

      Affiliations

    • Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan
    • ,
  • Te-Wei Lee

      Affiliations

    • Institute of Nuclear Energy Research, Longtan 32546, Taiwan
    • ,
  • Jem-Mau Lo

      Affiliations

    • Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan
    • Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 30013, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan. Tel.: +886 3 5727308; fax: +886 3 5718649.

Received 7 November 2008 ,Revised 5 January 2009 ,Accepted 12 January 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0969-8051(09)00009-2

doi: 10.1016/j.nucmedbio.2009.01.006

Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 355-361 , May 2009

Article Tools

* Image Usage & Resolution